Share this Post!

The Food and Drug Administration (FDA) warns the public from the purchase and use of adulterated “NIKKO SPRAY ALL PURPOSE QUICK DRYING HIGH GLOSS ACRYLIC 150 LIGHT YELLOW” which detected significant levels of lead (Pb) upon the conduct of laboratory tests on the collected samples. Laboratory test results showed that the product contains lead which exceeded the maximum limit of 90 parts per million (ppm).

1. NIKKO SPRAY ALL PURPOSE QUICK DRYING HIGH GLOSS ACRYLIC 150 LIGHT YELLOW

Lead is a cumulative toxicant that affects multiple body systems and is particularly harmful to young children and can suffer profound and permanent adverse health effects, particularly affecting the development of the brain and nervous system. It also causes long-term harm in adults, including increased risk of high blood pressure and kidney damage. Exposure of pregnant women to high levels of lead can cause miscarriage, stillbirth, premature birth and low birth weight. There is no permissible level of exposure to lead that is known to be without harmful effects. (Source: https:///www.who.int/news-room/fact-sheets/detail/lead-poisoning-and-health)

In light of the foregoing, the public is advised not to purchase and use the aforementioned adulterated H/UHS product. The public is further advised to always check if a household/urban hazardous substances product is registered with the FDA prior purchase and use.

All concerned establishments are sternly warned and hereby directed to stop the manufacture, distribution and sale of the aforementioned product. Appropriate regulatory sanction shall be executed to establishments that are continuously marketing these products, upon issuance of this advisory.

All FDA Regional Field Offices and Regulatory Enforcement Units, in coordination with law enforcement agencies and Local Government Units, are requested to ensure that violative products are not sold or made available in the market or areas of jurisdiction.

To file a report of unregistered products and establishments, please contact FDA thru the email address: [email protected].

Dissemination of this advisory to all concerned is hereby requested.

Attachments